Enfortumab vedotin + pembrolizumab nella prima linea del la/mUC: l'esperienza clinica italiana

[Oncoinfo – Oncology Snapshots: follow us on http://oncoinfo.it] The combination of enfortumab vedotin and pembrolizumab is finally available in Italy for the first-line treatment of locally advanced and metastatic urothelial carcinoma. The 2.5-year follow-up of the EV-302/KEYNOTE-A39 trial confirms and strengthens the survival data with EV + P in la/mUC. What is the real-world impact of these data on clinical practice? Patrizia Giannatempo (Department of Urological Surgical Oncology - Fondazione Istituto Nazionale Tumori IRCCS, Milan) shares the Italian experience.